Prostate最新文献

{"title":"Prospective Results of the Minimally Invasive Laser Enucleation of the Prostate (MiLEP).","authors":"Fu Feng, Zhanping Xu","doi":"10.1002/pros.24836","DOIUrl":"10.1002/pros.24836","url":null,"abstract":"","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":"407-408"},"PeriodicalIF":2.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142815050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of SGLT2 Inhibitor Initiation and PSA Response in Prostate Cancer.","authors":"Etan R Aber, Michael A Carducci, Channing J Paller, Sam R Denmeade, Kelli Rourke, Catherine H Marshall, Mark C Markowski","doi":"10.1002/pros.24841","DOIUrl":"10.1002/pros.24841","url":null,"abstract":"<p><strong>Introduction: </strong>Non-castrating therapies are an unmet clinical need for patients with advanced prostate cancer. To maximize quality of life and prioritize cardiovascular health, we investigated SGLT2 inhibitors as a non-castrating therapy in patients with prostate cancer.</p><p><strong>Materials and methods: </strong>We conducted a retrospective analysis of patients with either local or biochemically recurrent prostate cancer who initiated therapy with an SGLT2 inhibitor without concurrent androgen deprivation therapy. The primary endpoint was an estimated PSA₅₀ response rate. A secondary endpoint was PSA any response rate.</p><p><strong>Results: </strong>A total of nine patients (median age 63 years old; 44.4% Black; median PSA 3.7; 33.3% localized, 66.7% biochemically recurrent) were included. The PSA₅₀ and PSA_any response rate were 22.2% (N = 2/9) and 44.4% (N = 4/9), respectively.</p><p><strong>Conclusions: </strong>Patients with localized or biochemically recurrent prostate cancer achieved PSA responses to SGLT2 inhibitors. These findings justify prospective studies in patients with prostate cancer.</p>","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":"391-394"},"PeriodicalIF":2.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142873511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MiLEP Will be the New Goldstandard Procedure for BPH Treatment.","authors":"Luciano A Favorito","doi":"10.1002/pros.24837","DOIUrl":"10.1002/pros.24837","url":null,"abstract":"","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":"409"},"PeriodicalIF":2.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142815049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Histopathologic Features and Transcriptomic Signatures Do Not Solve the Issue of Magnetic Resonance Imaging-Invisible Prostate Cancers: A Matched-Pair Analysis.","authors":"Marco Oderda, Alessandro Marquis, Luca Bertero, Giorgio Calleris, Riccardo Faletti, Marco Gatti, Luca Mangherini, Giulia Orlando, Giancarlo Marra, Irene Ruggirello, Elena Vissio, Paola Cassoni, Paolo Gontero","doi":"10.1002/pros.24838","DOIUrl":"10.1002/pros.24838","url":null,"abstract":"<p><strong>Background: </strong>Multiparametric magnetic resonance imaging (mpMRI) is pivotal in prostate cancer (PCa) diagnosis, but some clinically significant (cs) PCa remain undetected. This study aims to understand the pathological and molecular basis for csPCa visibility at mpMRI.</p><p><strong>Methods: </strong>We performed a retrospective matched-pair cohort study, including patients undergoing radical prostatectomy (RP) for csPCa (i.e., ISUP grade group ≥ 2) from 2015 to 2020, in our tertiary-referral center. We screened for inclusion in the \"mpMRI-invisible\" cohort all consecutive men (N = 45) having a negative preoperative mpMRI. The \"mpMRI-visible\" cohort was matched based on age, PSA, prostate volume, ISUP grade group. Included patients underwent radiological and pathological open-label revisions and characterization of the tumor mRNA expression profile (analyzing 780 gene transcripts, signaling pathways, and cell-type profiling). We compared the clinical-pathological variables and the gene expression profile between matched pairs. The analysis was stratified according to histological characteristics and lesion diameter.</p><p><strong>Results: </strong>We included 34 patients (17 per cohort); mean age at RP and PSA were 70.5 years (standard deviation [SD] = 7.7), 7.1 ng/mL (SD = 3.3), respectively; 65% of men were ISUP 2. Overall, no significant differences in histopathological features, tumor diameter and location, mRNA profile, pathways, and cell-type scores emerged between cohorts. In the stratified analysis, an upregulation of cell adhesion and motility, of extracellular matrix remodeling and of metastatic process pathways was present in specific subgroups of mpMRI-invisible cancers.</p><p><strong>Conclusions: </strong>No PCa pathological or gene-expression hallmarks explaining mp-MRI invisibility were identified. Aggressive features can be present both in mpMRI-invisible and -visible tumors.</p>","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":"374-384"},"PeriodicalIF":2.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11776441/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142815048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PSA Density and Lesion Volume: Key Factors in Avoiding Unnecessary Biopsies for PI-RADS 3 Lesions.","authors":"Ali Ayranci, Ufuk Caglar, Huseyin Burak Yazili, Feyzi Sinan Erdal, Akif Erbin, Omer Sarilar, Faruk Ozgor","doi":"10.1002/pros.24840","DOIUrl":"10.1002/pros.24840","url":null,"abstract":"<p><strong>Introduction: </strong>The use of multiparametric magnetic resonance imaging (MRI) to guide prostate biopsies has improved cancer detection rates, particularly for high-grade tumors. However, despite guidelines recommending biopsies for lesions with a Prostate Imaging-Reporting and Data System (PI-RADS) score ≥ 3, the clinical significance of PI-RADS 3 lesions remains uncertain. This uncertainty, coupled with the cost and potential complications of biopsies, underscores the need for more accurate risk stratification strategies to avoid unnecessary procedures. Prostate-specific antigen density (PSAD) and index lesion volume are emerging as potential contributors to improve risk assessment.</p><p><strong>Materials and methods: </strong>This was a retrospective analysis of patients who had undergone an MRI-guided transrectal ultrasound (TRUS) prostate biopsy at a tertiary care institution. Patients with PI-RADS 3 lesions were included, and data on demographics, prostate-specific antigens (PSA), PSAD, lesion diameter, and pathology results were collected. The relationships between PSAD, lesion volume, and pathology outcomes were statistically analyzed.</p><p><strong>Results: </strong>Of the 213 patients included, 40 were diagnosed with prostate cancer. PSAD and PSAD x lesion diameter were significantly higher in the patients diagnosed with prostate cancer than those with benign lesions. Among the prostate cancer patients, clinically significant prostate cancer (csPCa) had a higher mean PSAD value than clinically insignificant prostate cancer (cisPCa). ROC analysis found PSAD x lesion diameter to have the highest discriminatory power for detecting csPCa.</p><p><strong>Discussion: </strong>MRI-guided biopsies offer targeted sampling but the clinical significance of PI-RADS 3 lesions remains uncertain. Index lesion volume and PSAD are promising adjunctive markers for risk assessment. Combining these factors could facilitate the avoidance of unnecessary biopsies and improve the detection of csPCa.</p><p><strong>Conclusion: </strong>Incorporating PSAD and index lesion volume into biopsy decision-making may enhance risk stratification, particularly for PI-RADS 3 lesions. Further research is needed to validate these findings and enhance the risk assessment strategies used in making decisions regarding prostate biopsy.</p>","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":"385-390"},"PeriodicalIF":2.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142830883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Pelvic Lymph Node Dissection on Early Oncological Outcomes in Intermediate-Risk Prostate Cancer Patients With Node-Negative PSMA PET.","authors":"Baris Esen, Hulya Seymen, Ayşe Armutlu, Ersin Koseoglu, Ibrahim Can Aykanat, Hatice Zoroğlu, Abdullah Erdem Canda, Yakup Kordan, Mevlana Derya Balbay, Dilek Ertoy Baydar, Mehmet Onur Demirkol, Derya Tilki, Tarık Esen","doi":"10.1002/pros.24884","DOIUrl":"https://doi.org/10.1002/pros.24884","url":null,"abstract":"<p><strong>Background: </strong>PSMA PET/CT has previously shown superior performance in nodal staging of prostate cancer (PCa) and may be used to reduce the number of unnecessary PLND procedures. This study aims to assess the performance of PSMA PET/CT in nodal staging of intermediate-risk prostate cancer and to evaluate the effect of PLND on oncological outcomes of intermediate-risk prostate cancer patients with a negative PSMA PET/CT.</p><p><strong>Methods: </strong>A total of 308 patients with intermediate-risk PCa who underwent PSMA PET/CT for nodal staging between January 2014 and July 2024 were included in the study. Patients who underwent PLND had higher PSA and higher rates of PIRADS-5 and biopsy grade-group 3 disease. A 1:1 propensity score matching was performed to eliminate patient characteristics differences between groups and 140 patients were included in the final analysis. PSA persistence rates ( ≥ 0.1 ng/dL) and biochemical recurrence (BCR; ≥ 0.2 ng/dL) rates after RP were recorded. Kaplan-Meier curves were constructed to evaluate oncological outcomes. Log-rank test was utilized to compare oncological outcomes in patients with and without PLND.</p><p><strong>Results: </strong>The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of PSMA PET/CT on nodal staging were 53.3%, 95%, 47.1%, and 96.1%, respectively. The NPV of PSMA PET/CT in patients with biopsy GG3 disease (96.3%) was similar to those with biopsy GG2 disease (95.6%). The median follow-up after propensity score matching was 20.7 months. The 24-month BCR-free survival rates were 83.7% and 86.9% in the PLND-RP group and RP-only groups, respectively (p = 0.078).</p><p><strong>Conclusions: </strong>NPV of PSMA PET/CT in determining LNI was remarkable in patients with intermediate-risk PCa and PLND was found to have no impact on oncological outcomes. Therefore PLND may be omitted to decrease surgery-related complications in patients with intermediate-risk PCa a negative PSMA PET/CT for nodal staging.</p>","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":"e24884"},"PeriodicalIF":2.6,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143517435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Diagnostic Value of Plasma Small Extracellular Vesicle-Derived CAIX Protein in Prostate Cancer and Clinically Significant Prostate Cancer: A Study on Predictive Models.","authors":"Haotian Chen, Bairen Pang, Zhihan Liu, Benjie Li, Qi Wang, Baokun Fan, Meng Han, Jie Gong, Cheng Zhou, Yingzhi Chen, Yong Li, Junhui Jiang","doi":"10.1002/pros.24879","DOIUrl":"https://doi.org/10.1002/pros.24879","url":null,"abstract":"<p><strong>Background: </strong>Current diagnostic tools are inaccurate and not specific to prostate cancer (PCa) diagnosis. Cancer-derived small extracellular vehicles (sEVs) play a key role in intercellular communication. In this study, we examined the diagnostic value of plasma sEV-derived carbonic anhydrase IX (CAIX) protein for PCa and clinically significant prostate cancer (csPCa) diagnosis and avoiding unnecessary biopsies.</p><p><strong>Methods: </strong>Plasma samples (n = 230) were collected from the patients who underwent prostate biopsy with elevated prostate-specific antigen (PSA) levels. sEVs were isolated and characterized, and sEV protein CAIX was measured using an enzyme-linked immunosorbent assay. Independent predictors of csPCa (Gleason score ≥ 7) were identified, and a predictive model was established. A Nomogram for predicting csPCa was developed using data from the training cohort.</p><p><strong>Results: </strong>The expression of sEV protein CAIX was significantly higher in both PCa and csPCa compared to benign patients and nonsignificant PCa (nsPCa) (Gleason score < 7, p < 0.001). sEV protein CAIX performed well in distinguishing PCa from benign patients. The predictive model defined by sEV protein CAIX and PSA density (PSAD) demonstrated the highest discriminative ability for csPCa (AUC = 0.895), with diagnostic sensitivity and specificity of 82.5% and 85.8%, respectively. Furthermore, sEV protein CAIX is an effective predictor of 2-year biochemical recurrence (BCR) in PCa patients (p = 0.013), and its high expression is significantly associated with poorer BCR-free survival (p < 0.05).</p><p><strong>Conclusions: </strong>Our findings demonstrate the excellent performance of sEV protein CAIX in PCa and csPCa diagnosis. The Nomogram-based csPCa predictive model incorporating sEV protein CAIX and PSAD exhibits strong predictive value. Additionally, assessing plasma sEV protein CAIX expression levels can further aid in evaluating patient prognosis and provide a basis for making effective treatment decisions.</p>","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143517438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Role of Secondary Lesion Biopsy in Detecting Clinically Significant Prostate Cancer.","authors":"Trevor C Hunt, Zijing Cheng, Ashley Li, Anthony J Pamatmat, David Song, Tony Zhao, Gary M Hollenberg, Eric P Weinberg, Jathin Bandari, Thomas Osinski","doi":"10.1002/pros.24870","DOIUrl":"https://doi.org/10.1002/pros.24870","url":null,"abstract":"<p><strong>Background: </strong>Multiparametric MRI (mpMRI) and fusion-targeted biopsy (TB) have improved the detection of clinically significant prostate cancer (csPCa); however, it remains unclear whether secondary lesions (SLs) identified on mpMRI must also be biopsied in addition to the index lesion (IL). Currently, American Urological Association and European Association of Urology guidelines suggest biopsying all lesions, but supporting data are sparse. This study examines whether including SL biopsies provides additional value in csPCa detection compared to IL biopsy alone when systematic biopsy (SB) is also performed.</p><p><strong>Methods: </strong>Men with multiple PI-RADS ≥ 3 lesions on mpMRI who underwent prostate biopsy were retrospectively identified. The primary analysis compared csPCa detection rates from SB and IL TB, with or without SL TB. Secondary analyses assessed the impact of prostate-specific antigen (PSA) density and SL PI-RADS scores on csPCa detection. Sensitivity analyses were performed to investigate the robustness of findings.</p><p><strong>Results: </strong>Among 73 men, csPCa detection rate was 47% with SB and IL biopsy alone and improved to 52% with SL biopsies included (p = 0.62). Secondary analyses showed no significant differences in csPCa detection based on PSA density or SL PI-RADS scores. Two of three sensitivity analyses supported the primary findings.</p><p><strong>Conclusions: </strong>Biopsying SLs does not significantly increase csPCa detection rates compared to IL biopsy alone when SB is also performed. This supports the notion that SL biopsies can be safely omitted without compromising clinical outcomes, thereby potentially reducing patient discomfort and procedural costs, and may inform future guideline development and revisions.</p>","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":"e24870"},"PeriodicalIF":2.6,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143484587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Translation, Cross-Cultural Adaptation, and Psychometric Validation of the Turkish Version of the \"Expanded Prostate Cancer Index Composite (EPIC)\" in Prostate Cancer Patients.","authors":"Burak Tilki, Pervin Hurmuz, Deniz Yuce, Gokhan Ozyigit, Fadil Akyol","doi":"10.1002/pros.24878","DOIUrl":"https://doi.org/10.1002/pros.24878","url":null,"abstract":"<p><strong>Purpose: </strong>The Expanded Prostate Cancer Index Composite (EPIC) is a symptom scale that measures health-related quality of life (HRQoL) in prostate cancer (PCa) patients. This scale is translated into different languages and used in daily practice. This study aimed to translate the EPIC scale into Turkish and provide Turkish validation by conducting validity and reliability analyses.</p><p><strong>Methods: </strong>Patients with biopsy-proven PCa who received definitive or postoperative radiotherapy (RT) at our department were included. All participants were evaluated using the Turkish EPIC, The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ) C30, and EORTC-QLQ PR25 questionnaires at five different time points. First, the original English version of the EPIC was translated into Turkish, and then, two reliability and five validity analyses were performed.</p><p><strong>Results: </strong>One hundred-five patients were included in the study. In the reliability analyses, Cronbach's alpha values of the whole scale were measured at 0.866, and the main scales' Cronbach's alpha values were measured between 0.654 and 0.969. In the test-retest analysis, the correlation values of the main scales were measured between 0.413 and 0.861. The pilot study with 20 patients was completed, thus providing face validity. Sensitivity to change analysis, interscale correlation, criterion validity, and explanatory factor analyses were performed, and results proving the scale's validity were obtained in all analyses.</p><p><strong>Conclusion: </strong>The Turkish EPIC scale is applicable for patients in the Turkish population diagnosed with PCa who received either definitive or postoperative RT.</p>","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":"e24878"},"PeriodicalIF":2.6,"publicationDate":"2025-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143484589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Neoadjuvant Chemohormonal Therapy With GnRH Antagonist and Low-Dose Estramustine in Very High-Risk Prostate Cancer Undergoing Robotic Radical Prostatectomy.","authors":"Takanari Kambe, Masashi Kubota, Toshinari Yamasaki, Mutsushi Kawakita, Shiori Murata, Yuto Hattori, Yoichiro Tohi, Yuya Sekine, Ryoma Kurahashi, Kimihiro Shimatani, Atsuro Sawada, Hiromitsu Negoro, Ryoichi Saito, Takayuki Goto, Takashi Kobayashi","doi":"10.1002/pros.24875","DOIUrl":"https://doi.org/10.1002/pros.24875","url":null,"abstract":"<p><strong>Background: </strong>High-risk patients with prostate cancer (PC) frequently experience biochemical recurrence (BCR) after surgery. Thus numerous studies have investigated the efficacy of neoadjuvant therapies for high-risk PC patients; however, no protocol has been established. This study aimed to assess the effect of androgen deprivation therapy combined with low-dose estramustine phosphate (EMP) on BCR compared with androgen deprivation therapy (ADT) alone in high- and very high-risk patients with PC.</p><p><strong>Methods: </strong>This retrospective study targeted patients with PC meeting the National Comprehensive Cancer Network high-risk criteria (cT1-4N0M0), with 173 patients in the exposure group who received neoadjuvant chemohormonal therapy (gonadotropin-releasing hormone [GnRH] antagonist combined with low-dose EMP), and 490 patients in the control group treated with and neoadjuvant hormone therapy (NHT) (ADT ± first-generation anti-androgens). Data for each group were extracted from a database of patients who underwent robot-assisted laparoscopic prostatectomy at 25 tertiary care centers across Japan between 2011 and 2023. The inverse probability of treatment weighting was used to adjust for baseline differences. The primary outcome was BCR-free survival, with hazard ratios (HRs) calculated using a Cox proportional hazards model between the high-risk and very high-risk groups.</p><p><strong>Results: </strong>After adjustment, the standardized mean difference was < 0.1. The exposure group had 3 and 5-year BCR-free survival rates of 82.1% and 74.6%, respectively, compared with 70.8% and 64.4% in the control group (HR: 0.55; 95% confidence interval [CI]: 0.35-0.88). For high-risk patients, the rates were 87.1% and 84.2% at both 3 and 5 years in the intervention group and 83.5% and 75.0% in the control group (HR: 0.66; 95% CI: 0.30-1.47). For very high-risk patients, the 3-year and 5-year rates were 75.3% and 65.7% in the intervention group and 57.3% and 53.6% in the control group (HR: 0.53; 95% CI: 0.30-0.92).</p><p><strong>Conclusions: </strong>In patients with very high-risk PC undergoing robot-assisted laparoscopic prostatectomy, a GnRH antagonist and low-dose EMP yielded better BCR-free survival outcomes than NHT.</p>","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":"e24875"},"PeriodicalIF":2.6,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143460585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}